1 Cancer Stock to Buy and Hold for the Next Decade

Patrick Bafuma, The Motley Fool
·4 min read
1 Cancer Stock to Buy and Hold for the Next Decade

Down 11% since the beginning of the year, but up just less than fivefold over the past five years , Blueprint Medicines (NASDAQ: BPMC) has two products on the market and a clear path to continue to achieve big gains for investors in the future. Blueprint Medicines is the first and only company to have two internally discovered and developed medicines that received U.S. Food and Drug Administration (FDA) approval within a decade of founding. Ayvakit was approved for rare forms of a type of stomach cancer in January 2020.